These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37637734)

  • 21. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Aljasser A; Colon-Ascanio M; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais PR; Tan H; Wang J; Chen Y; Choy JS
    PLoS Pathog; 2023 Aug; 19(8):e1011592. PubMed ID: 37651467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    Res Sq; 2022 Aug; ():. PubMed ID: 36052369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contributions of Hyperactive Mutations in M
    Flynn JM; Zvornicanin SN; Tsepal T; Shaqra AM; Kurt Yilmaz N; Jia W; Moquin S; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2024 Apr; 10(4):1174-1184. PubMed ID: 38472113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
    Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Li J; Wang Y; Solanki K; Atre R; Lavrijsen M; Pan Q; Baig MS; Li P
    Antiviral Res; 2023 Mar; 211():105555. PubMed ID: 36791846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
    Hung YP; Lee JC; Chiu CW; Lee CC; Tsai PJ; Hsu IL; Ko WC
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms.
    Ramos-Guzmán CA; Andjelkovic M; Zinovjev K; Ruiz-Pernía JJ; Tuñón I
    Chem Sci; 2023 Mar; 14(10):2686-2697. PubMed ID: 36908962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.
    Tan B; Zhang X; Ansari A; Jadhav P; Tan H; Li K; Chopra A; Ford A; Chi X; Ruiz FX; Arnold E; Deng X; Wang J
    bioRxiv; 2023 Dec; ():. PubMed ID: 38076941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structures of main protease (M
    Jiang H; Zou X; Zeng P; Zeng X; Zhou X; Wang J; Zhang J; Li J
    Mol Biomed; 2023 Aug; 4(1):23. PubMed ID: 37532968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease.
    Flynn JM; Huang QYJ; Zvornicanin SN; Schneider-Nachum G; Shaqra AM; Yilmaz NK; Moquin SA; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2023 Jul; 9(7):1372-1386. PubMed ID: 37390404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamical Nonequilibrium Molecular Dynamics Simulations Identify Allosteric Sites and Positions Associated with Drug Resistance in the SARS-CoV-2 Main Protease.
    Chan HTH; Oliveira ASF; Schofield CJ; Mulholland AJ; Duarte F
    JACS Au; 2023 Jun; 3(6):1767-1774. PubMed ID: 37384148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 M
    Chen SA; Arutyunova E; Lu J; Khan MB; Rut W; Zmudzinski M; Shahbaz S; Iyyathurai J; Moussa EW; Turner Z; Bai B; Lamer T; Nieman JA; Vederas JC; Julien O; Drag M; Elahi S; Young HS; Lemieux MJ
    ACS Cent Sci; 2023 Apr; 9(4):696-708. PubMed ID: 37122453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.
    Brewitz L; Dumjahn L; Zhao Y; Owen CD; Laidlaw SM; Malla TR; Nguyen D; Lukacik P; Salah E; Crawshaw AD; Warren AJ; Trincao J; Strain-Damerell C; Carroll MW; Walsh MA; Schofield CJ
    J Med Chem; 2023 Feb; 66(4):2663-2680. PubMed ID: 36757959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
    Moghadasi SA; Biswas RG; Harki DA; Harris RS
    Res Sq; 2023 Mar; ():. PubMed ID: 36993515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.
    Lo CW; Kariv O; Hao C; Gammeltoft KA; Bukh J; Gottwein J; Westberg M; Lin MZ; Einav S
    Antiviral Res; 2024 Nov; 231():106022. PubMed ID: 39424074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
    Moghadasi SA; Biswas RG; Harki DA; Harris RS
    bioRxiv; 2023 Feb; ():. PubMed ID: 36909573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
    Xia Z; Sacco M; Hu Y; Ma C; Meng X; Zhang F; Szeto T; Xiang Y; Chen Y; Wang J
    ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1408-1421. PubMed ID: 34414360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.